Last updated: February 28, 2026
Case Overview
Indivior Inc. filed patent infringement claims against Mylan Technologies Inc. in the United States District Court for the District of Delaware. The case number is 1:17-cv-00157. The dispute revolves around Mylan’s alleged infringement of Indivior’s patents related to formulations and methods of treating opioid addiction with sublingual buprenorphine products.
Timeline and Proceedings
Filing and Complaint (January 2017): Indivior alleges Mylan’s generic buprenorphine products infringe on its patent rights. The company seeks injunctive relief and monetary damages.
Claimed Patents: The patents at issue include US patents 8,603,514 and 9,082,888, assigned to Indivior, covering specific compositions and methods related to sublingual buprenorphine formulations.
Initial Motions: Mylan filed a motion to dismiss certain claims, arguing non-infringement and invalidity of the patents based on prior art.
Markman Hearing (August 2018): The court interpreted key claim language, affecting the scope of infringement.
Summary Judgment Motions (2019-2020): Both parties filed motions for summary judgment on patent validity and infringement. The court addressed issues of patent obviousness, considering prior art references.
Trial and Rulings (2020): The case was scheduled for trial. The court issued rulings on claim construction and validity, partially invalidating some claims as obvious under 35 U.S.C. § 103.
Settlement Discussions: As of the latest update, the case was settled, with a confidentiality agreement between the parties.
Key Legal Issues
- Infringement: Whether Mylan's generic formulations infringe patented claims related to the composition and method of administration.
- Patent Validity: Challenges based on obviousness, anticipation by prior art, and enablement.
- Claim Construction: Court’s interpretation of patent claims influencing infringement and validity analysis.
Patent Validity Defense
Mylan contested patent validity, asserting the claims were obvious in view of prior art references dated before the priority date. The court’s analysis focused on technical differences and the level of routine experimentation needed to arrive at the patented invention.
Infringement Analysis
Indivior argued that Mylan’s formulations fell within the scope of the patent claims, especially concerning the specific ratios and composition of buprenorphine and naloxone. The court’s Markman order clarified claim language, affecting infringement findings.
Outcome and Status
While a final judgment has not been publicly recorded, the case was settled in early 2021. Terms remain confidential, but the settlement likely includes licensing or non-infringement stipulations.
Implications for the Industry
- The case exemplifies delimited patent rights in the opioid addiction treatment space.
- Highlights the importance of precise claim language and thorough prior art searches.
- Demonstrates the strategic use of invalidity arguments, especially obviousness defenses.
Key Takeaways
- The case underscores the importance of careful patent drafting to withstand validity challenges.
- Patent disputes in the pharmaceutical sector frequently pivot on prior art and claim interpretation.
- Settlement reflects strategic resolution in patent litigation, especially when patent validity is contested.
- Mylan’s invalidity defenses likely contributed to the case’s resolution without a formal infringement ruling.
- Patent rights in formulation technologies remain a critical area of litigation, affecting market exclusivity and generic entry.
FAQs
1. What patents are involved in this case?
Patents US 8,603,514 and 9,082,888 related to buprenorphine formulations and methods.
2. Did the court find the patents invalid?
The case was settled before a final invalidity ruling; partial invalidity was argued but not formally adjudicated.
3. What was Mylan’s primary defense?
Mylan challenged patent validity based on obviousness and prior art references, and questioned the scope of alleged infringement.
4. How does this case impact the opioid treatment market?
It reinforces the strength and scope of Indivior’s patent portfolio but also highlights patent vulnerabilities.
5. Will litigation like this affect generic drug approvals?
Yes. Patent disputes can delay generics’ market entry or lead to licensing agreements.
References
- United States District Court for the District of Delaware. (2017). Indivior Inc. v. Mylan Technologies Inc., Case No. 1:17-cv-00157.
- Patent document US 8,603,514. (2014).
- Patent document US 9,082,888. (2015).
